Salute e Benessere

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Media ReleaseCOPENHAGEN, Denmark; February 12, 2025 Genmab filed Form 20-F for the financial year 2024 with the U.S. SEC Genmab A/S(Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2024 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Genmab A/S Annual Report 2024.Both reports are available via the SEC's website,www.sec.govand Genmab's website,www.genmab.com...
Nasdaq GlobeNewswire
12/02/2025

DNA Health & Wellness Brings Advanced Preventative Health and Longevity…

Spanning over 11,000 square feet, the new clinic is poised to be one of the largest and most advanced health optimisation and longevity centres in the region, offering a comprehensive range of personalised treatments that focus on prevention, optimisation, rejuvenation, and longevity. The facility integrates cutting-edge technologies, including advanced diagnostic imaging, advanced blood testing, AI-based reporting software, and precision medicine therapies. Spanning over 11,000 square feet,...
PR Newswire
12/02/2025

EssilorLuxottica: Q4/FY 2024 Results - Sound sales growth and margin expansion…

Sound sales growth and margin expansion in 2024Smartglasses as a new driver, Nuance off to a promising startGroup revenue at constant exchange rates 1+9.2% in Q4 and +6.0% in the FYNorth America accelerating in Q4, with SGH positive; sound EMEA driven by both PS and DTCRay-Ban Meta at 2 million units sold since the launch, with strong acceleration in 2024Nuance Audio cleared, starting off in the US OTC and EuropeStellest continuing to be strong in China, up approx...
Nasdaq GlobeNewswire
12/02/2025

Plasma Fractionation Market Forecast to Grow at 7.8% CAGR, Hitting USD 50.1…

IMR
12/02/2025

FDA approves Roche's Evrysdi tablet as first and only tablet for Spinal Muscular…

Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and safety as the currently available oral solutionNew tablet formulation may provide greater freedom and independence for people with SMA thanks to simplified dose administrationBasel, 12 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug...
Nasdaq GlobeNewswire
12/02/2025

Groupe Casino - Nombre de droits de vote et d'actions 31-01-2025

CASINO, GUICHARD-PERRACHON Société anonyme au capital de 4 009 397,13 € Siège social : 1, Cours Antoine Guichard 42000 Saint-Etienne 554 501 171 R.C.S. Saint-Etienne Informations relatives au nombre total de droits de vote et d'actions composant le capital social au 31 janvier 2025(article 223-16 du Règlement Général de l'Autorité des Marchés Financiers)Nombre d'actions composant le capitalNombre total de droits de voteNombre total de droits de vote exerçables en...
Nasdaq GlobeNewswire
12/02/2025

NEOM Investment Fund partners with Paradromics to drive innovation in…

Led by NEOM's strategic investment arm, NEOM Investment Fund (NIF), the partnership will advance the development of BCI-based therapies, which aim to restore, enhance or replace lost neurological functions for individuals with conditions that impair movement, communication or cognitive function. As part of the agreement, a Brain-Computer Interface Center of Excellence will be established within NEOM to spearhead ambitious clinical research and eventually serve as the premier center for BCI-based…
PR Newswire
12/02/2025

Genmab Publishes 2024 Annual Report

Company Announcement COPENHAGEN, Denmark; February 12, 2025 –Genmab A/S(Nasdaq: GMAB) announced today the publication of its Annual Report for 2024.Below is a summary of business progress in 2024, financial performance for the year and the financial outlook for 2025. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company's website,www.genmab.com/investor-relations. Conference CallGenmab will hold a conference...
Nasdaq GlobeNewswire
12/02/2025

Clinical Decision Support Systems Market to Grow from USD 1.9 Billion in 2023 to…

IMR
12/02/2025

Cell Counting Market to Hit USD 16.14 Billion by 2029 with 7.7% CAGR |…

Browse in-depth TOC on "Cell Counting Market" Browse in-depth TOC on "Cell Counting Market" 771 - Tables55 - Figures511 - Pages Based on product, the cell counting market is segmented into consumables and instruments. The consumables segment is further divided into media, sera & reagents, assay kits, microplates, accessories, and other consumables. The instrument segment is further divided into spectrophotometers, flow cytometers, hematology analyzers, cell counters,...
PR Newswire
12/02/2025

Cell Analysis Market to Grow from USD 19.2 Billion in 2023 to USD 38.4 Billion…

IMR
12/02/2025

Joint Replacement Devices Market to Hit USD 31.09 Billion by 2030 with 4.8% CAGR…

Browse in-depth TOC on "Joint Replacement Devices Market" Browse in-depth TOC on "Joint Replacement Devices Market" 333 - Tables63 - Figures375 - Pages The joint replacement devices market is segmented based on product into knee replacement devices, hip replacement devices, shoulder replacement devices, elbow replacement devices, ankle implants, wrist replacement devices, other replacement devices, and bone graft substitutes. The knee replacement devices segment is...
PR Newswire
12/02/2025

Board member Roland Norberg requests to resign from the Board

Aino Health AB's board member Roland Norberg has today, 12 February 2025, requested to resign from the company's board. The reason for the resignation is that the company that nominated Roland Norberg, Norberg & Partner Sustainable Group AB (publ), has sold all its shares in Aino Health AB. A new Board of Directors will be appointed at this spring's Annual General Meeting.For more informationJyrki Eklund CEO, Aino Health Phone: +358 40 042 [email protected]...
Nasdaq GlobeNewswire
12/02/2025

TriNetX and Fujitsu Launch Joint Venture to Increase Japanese Patients' Access…

The initiative represents a significant step forward for integrating Japan into the global landscape of data-driven medicine and healthcare innovation. With its status as the third-largest pharmaceutical market worldwide, Japan offers unparalleled opportunities for clinical research and drug development. Additionally, Japan'srapidly aging population provides an ideal foundation for studying age-related conditions such as cancer, cardiovascular diseases, and neurodegenerative disorders. The...
PR Newswire
12/02/2025

DOC Pharma: A New Identity for the Generic Drugs Company, Advancing Growth By…

Since 2017, DOC has undertaken a journey to strengthen its presence in the pharmaceutical market, beginning with expanding its product offerings in multiple therapeutic areas. Since then, the generic drug portfolio has been complemented by the ophthalmic product line, integrated in 2022 through the acquisition of Medivis's portfolio, and the muscle relaxant product line, through the Muscoril® acquisition which has now closed.Today, DOC Pharma is announcing the expansion of its...
PR Newswire
12/02/2025

T-knife Therapeutics to Participate in Two Investor Conferences in March 

SAN FRANCISCO and BERLIN, Feb.12, 2025(GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, today announced that members of the company's management team will participate in two investor conferences in March. TD Cowen 45 thAnnual Health Care Conference from March 3-5, 2025 in Boston, MALeerink Partners Global Healthcare Conference from March 10-12, 2025 in Miami, FL About...
Nasdaq GlobeNewswire
12/02/2025

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

LONDON and NEW YORK, Feb.12, 2025(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that its lead asset, OK-101, has been officially assigned the United States Adopted Name (USAN) "urcosimod".The…
Nasdaq GlobeNewswire
12/02/2025

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended…

— ALKS 2680 Phase 2 Studies in Narcolepsy Type 1 and Type 2 Ongoing With Data Expected in H2 2025 — — ALKS 2680 Phase 2 Studies in Narcolepsy Type 1 and Type 2 Ongoing With Data Expected in H2 2025 — DUBLIN , Feb. 12, 2025 /PRNewswire/ -- Alkermes plc(Nasdaq: ALKS) today reported financial results for the quarter and year endedDec. 31, 2024and provided financial expectations for 2025. "2024 marked the completion of a multi-year effort to transition the business into...
PR Newswire
12/02/2025

Philanthropic Partnership Launches New Initiative Tackling Antimicrobial…

The Gr-ADI is the first investment of the $300 millionglobal health research and development partnership launched by these three philanthropic organizations last year. The broader partnership will support science and innovation to advance solutions to health challenges that disproportionately impact people in low- and middle-income countries (LMICs), including climate and sustainability; infectious diseases; and the interplay between nutrition, immunity, infectious diseases, cardiometabolic and…
PR Newswire
12/02/2025

Diamyd Medical announces expanded financial support from Breakthrough T1D

"We are thrilled to strengthen our collaboration with Breakthrough T1D as we work towards bringing our antigen-specific immunotherapy to market," says Ulf Hannelius, CEO of Diamyd Medical. "This additional funding is a testament to the potential of our approach in accelerating patient recruitment and preparations ahead of a potential accelerated approval." "We are thrilled to strengthen our collaboration with Breakthrough T1D as we work towards bringing our…
PR Newswire
12/02/2025

QuantalX Neuroscience Announces CE MDR Approval, Making Brain Health Assessment…

With CE MDR approval, QuantalX is set to scale the commercialization of its accessible and objective neurodiagnosis test across Europe. The Delphi-MD device will be deployed in neurological care centers, neurology departments, and brain health networks. Delphi-MD will streamline improved brain health assessment, early detection and differential diagnosis of any brain abnormality or disease such as stroke, Parkinson disease, dementia, Alzheimer's disease, Normal Pressure Hydrocephalous (NPH) and…
PR Newswire
12/02/2025

ASTON MARTIN ARAMCO UNVEIL TRAILBLAZING PARTNERSHIP WITH ELEMIS, UNITING LUXURY…

Fusing treatments with next-generation technology and clinically-proven skincare for decades, ELEMIS are passionate about empowering their communities with confidence. Through the partnership with the British team, the luxury brand now aims to promote inclusivity within the world of Formula 1, which has recently seen a shift in fan demographic. The latest study by Nielson indicates that 41% of fans are women, and the fastest growing fanbase, women aged 16 to 24. The focus on inclusion...
PR Newswire
12/02/2025

Implantica announces Module 1 is accepted and closed by FDA in the PMA…

Implantica's Founder, CEO, and Inventor of RefluxStop, Dr. Peter Forsell says, "We are grateful to FDA for their substantive review and acceptance of our Module 1 submission. We look forward to receiving FDA's feedback on Module 2, which is expected in the very near-term and is - from our perspective - the absolutely key module that includes the remarkable 5-year Clinical study outcomes of RefluxStop™." Implantica's Founder, CEO, and Inventor of RefluxStop, Dr.Peter Forsellsays…
PR Newswire
12/02/2025

Medicover: Year-end report January-December 2024

REVENUE AND EARNINGS REVENUE AND EARNINGS Definition and reconciliation of alternative performance measures are available atwww.medicover.com/financial-information. CEO STATEMENT "In 2024, we have continued our impressive growth journey and capitalised on the significant growth investments in previous years. We focused on business as usual, meaning filling up capacity in the hospital network, enhancing operational efficiency, broadening our service offering and integrating...
PR Newswire
12/02/2025
Altri  Comunicati